← Back to Screener
Scholar Rock Holding Corporation Common Stock (SRRK)
Price$47.80
Favorite Metrics
Price vs S&P 500 (26W)32.57%
Price vs S&P 500 (4W)1.34%
Market Capitalization$5.49B
All Metrics
Book Value / Share (Quarterly)$2.26
P/TBV (Annual)3.25x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.77
Price vs S&P 500 (YTD)4.58%
Net Profit Margin (TTM)-236.96%
EPS (TTM)$-3.30
10-Day Avg Trading Volume1.52M
EPS Excl Extra (TTM)$-3.30
EPS (Annual)$-2.47
ROI (Annual)-58.81%
Net Profit Margin (5Y Avg)-1236.36%
Cash / Share (Quarterly)$3.39
ROA (Last FY)-51.86%
EBITD / Share (TTM)$-3.32
ROE (5Y Avg)-60.37%
Operating Margin (TTM)-231.80%
Cash Flow / Share (Annual)$-2.77
P/B Ratio22.37x
P/B Ratio (Quarterly)18.30x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)111.37x
Net Interest Coverage (TTM)-809.50x
ROA (TTM)-96.69%
EPS Incl Extra (Annual)$-2.47
Current Ratio (Annual)6.95x
Quick Ratio (Quarterly)6.68x
3-Month Avg Trading Volume1.31M
52-Week Price Return55.45%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.98
P/S Ratio (Annual)165.45x
Asset Turnover (Annual)0.09x
52-Week High$51.63
Operating Margin (5Y Avg)-1238.26%
EPS Excl Extra (Annual)$-2.47
CapEx CAGR (5Y)-31.83%
Tangible BV CAGR (5Y)36.11%
26-Week Price Return39.46%
Quick Ratio (Annual)6.68x
13-Week Price Return2.73%
Total Debt / Equity (Annual)0.41x
Current Ratio (Quarterly)6.95x
Enterprise Value$5,267.594
Asset Turnover (TTM)0.16x
Book Value / Share Growth (5Y)-21.57%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-405.24%
Cash / Share (Annual)$3.39
3-Month Return Std Dev60.59%
Net Income / Employee (TTM)$-1
ROE (Last FY)-66.81%
EPS Basic Excl Extra (Annual)$-2.47
Receivables Turnover (TTM)1.23x
Total Debt / Equity (Quarterly)0.41x
EPS Incl Extra (TTM)$-3.30
ROI (TTM)-113.25%
P/S Ratio (TTM)116.10x
Pretax Margin (5Y Avg)-1236.36%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.04
Price vs S&P 500 (52W)20.81%
Year-to-Date Return8.51%
5-Day Price Return-3.53%
EPS Normalized (Annual)$-2.47
ROA (5Y Avg)-41.66%
Net Profit Margin (Annual)-405.24%
Month-to-Date Return-2.77%
Cash Flow / Share (TTM)$-1.95
EBITD / Share (Annual)$-2.45
Operating Margin (Annual)-404.85%
LT Debt / Equity (Annual)0.41x
ROI (5Y Avg)-50.42%
LT Debt / Equity (Quarterly)0.41x
EPS Basic Excl Extra (TTM)$-3.30
P/TBV (Quarterly)5.05x
P/B Ratio (Annual)18.30x
Pretax Margin (TTM)-236.96%
Book Value / Share (Annual)$2.26
Price vs S&P 500 (13W)0.35%
Beta0.74x
P/FCF (Annual)237.93x
Revenue / Share (TTM)$0.00
ROE (TTM)-145.91%
52-Week Low$27.07
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.35
4.36
4.36
4.36
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SRRKScholar Rock Holding Corporation Common Stock | 116.10x | — | — | — | $47.80 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Scholar Rock is a biopharmaceutical company developing treatments for rare neuromuscular diseases, with a focus on Spinal Muscular Atrophy. Its lead candidate, apitegromab, is in clinical development with both intravenous and subcutaneous formulations. The company's pipeline also includes SRK-439, a myostatin inhibitor in development for rare neuromuscular indications.